Regulation of cell proliferation, apoptosis, and carcinogenesis by activin

Experimental Biology and Medicine

Volumn 227, Issue 2, 2002, Pages 75-87

  Chen, Ye Guang ^a   Lui, Hannah M ^b   Lin, Shi Lung ^c   Lee, Jeffery M ^b   Ying, Shao Yao ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c Epiclone Inc   (United States)

Author keywords

Activin; Activin receptors; Activin binding protein; Apoptosis; Carcinogenesis; Cell proliferation; D RNAi; RNA PCR; Signaling pathway; Smad; Subtractive hybridization

Indexed keywords

ACTIVIN A; ACTIVIN RECEPTOR; PROTEIN BCL 2; PROTEIN P16; PROTEIN P21; PROTEIN P53; TRANSFORMING GROWTH FACTOR BETA;

APOPTOSIS; CANCER GROWTH; CARCINOGENESIS; CELL GROWTH; CELL PROLIFERATION; COVALENT BOND; HUMAN; KNOCKOUT GENE; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN FUNCTION; SHORT SURVEY; SIGNAL TRANSDUCTION;

EID: 0036486076     PISSN: 00379727     EISSN: None     Source Type: Journal    
DOI: 10.1177/153537020222700201     Document Type: Short Survey

References (180)

1. Ying SY. Inhibins, activins, and follistatins: gonadal proteins modulating the secretion of follicle-stimulating hormone. Endocrine Rev 9:267-293, 1988.
2. Vale W, Hsueh A, Rivier C, Yu J. The inhibin/activin family of hormones and growth factors. In: Sporn MB, Roberts AB, Eds. Peptide Growth Factors and Their Receptors. Heidelberg: Springer-Verlag, pp211-248, 1999.
3. Ying SY, Murata T. Molecular biology of the gonadal proteins: inhibin, activin, and follistatin. In: Gwatkin RBL, Ed. Genes in Mammalian Reproduction. New York: Wiley-Liss, pp207-228, 1993.
4. Mathews L. Activin receptors and cellular signaling by the receptor serine kinase family. Endocrine Rev 15:310-325, 1994.
5. Peng C, Mukai ST. Activins and their receptors in female reproduction. Biochem Cell Biol 78:261-279, 2000.
6. Batres Y, Zhang Z, Ying SY. Expression of activins and activin receptor messenger RNAs in LNCaP cells, a human prostatic adenocarcinoma cell line. Int J Oncol 6:1185-1188, 1995.
7. Furst AF, Zhang Z, Ying SY. Expression of activin and activin receptors in human prostatic carcinoma cell line DU-145. Int J Oncol 7:239-243, 1995.
8. Ying SY, Zhang Z, Xing W. Expression of activin and activin receptors in PC3 human prostatic cancer cells. Int J Oncol 6:601-606, 1995.
9. Ying SY, Zhang Z, Huang G, Hsieh HC. Inhibin/activin subunits and activin receptors in human breast cell lines and lactating rat mammary glands. Int J Oncoolgy 7:481-485, 1995.
10. Liu QY, Niranjan B, Gomes P, Gomm JJ, Davies D, Coombes RC, Buluwela L. Inhibitory effects of activin on the growth and morpholgenesis of primary and transformed mammary epithelial cells. Cancer Res 56:1155-1163, 1996.
11. Zhang Z. Ying SY. Expression of activins and activin receptors in human retinoblastoma cell line Y-79. Cancer Lett 89:207-214, 1995.
12. Jaffe GJ, Harrison CE, Lui GM, Roberts WL, Goldsmith PC, Mesiano S, Jaffe RB. Activin expression by cultured human retinal pigment epithelial cells. Invest Ophthal Visual Sci 35:2924-2931, 1994.
13. Minami S, Yamoto M, Nakano R. Immunohistochemical localization of inhibin/activin subunits in human placenta. Obst Gynecol 80:410-414, 1992.
14. La Rosa S, Uccella S, Billo P, Facco C, Sessa F, Capella C. Immunohistochemical localization of α- and β-subunits of inhibin/activin in human normal endocrine cells and related tumors of the digestive system. Virchows Arch 434:29-36, 1999.
15. Takahashi S, Uchimaru K, Harigaya K, Asano S, Yamashita T. Tumor necrosis factor and interleukin-1 induce activin A gene expression in a human bone marrow stromal cell line. Biochem Biophys Res Commun 188:310-317, 1992.
16. Vliegen MK, Schlatt S, Weinbauer GF, Bergmann M, Groome NP, Nieschlag E. Localization of inhibin/activin subunits in the testis of adult nonhuman primates and men. Cell Tissue Res 273:261-268, 1993.
17. Gurusinghe CJ, Healy DL, Jobling T, Mamers P, Burger HG. Inhibin and activin are demonstrable by immunohistochemistry in ovarian tumor tissue. Gynecol Oncol 57:27-32, 1995.
18. Otani T, Minami S, Kokawa K, Shikone T, Yamoto M, Nakano R. Immunohistochemical localization of activin A in human endometrial tissues during the menstrual cycle and in early pregnancy. Obstet Gynecol 91:685-692, 1998.
19. Petraglia F, Woodruff TK, Botticelli G, Botticelli A, Genazzani AR, Mayo KE, Vale W. Gonadotropin-releasing hormone, inhibin, and activin in human placenta: evidence for a common cellular localization. J Clin Endocrinol Metabol 74:1184-1188, 1992.
20. Sidis Y, Fujiwara T, Leykin L, Isaacson K, Toth T, Schneyer AL. Characterization of inhibin/activin subunit, activin receptor, and follistatin messenger ribonucleic acid in human and mouse oocytes: evidence for activin's paracrine signaling from granulosa cells to oocytes. Biol Reprod 59:807-812, 1998.
21. Spencer SJ, Rabinovici J, Jaffe RB. Human recombinant activin-A inhibits proliferation of human fetal adrenal cells in vitro. J Clin Endocrinol Metabol 71:1678-1680, 1990.
22. Furukawa M, Eto Y, Kojima I. Expression of immunoreactive activin A in fetal rat pancreas. Endocrine J 42:63-68, 1995.
23. Dolter KE, Palyash JC, Shao LE, Yu J. Analysis of activin A gene expression in human bone marrow stromal cells. J Cell Biochem 70:8-21, 1998.
24. Munz B, Hubner G, Tretter Y, Alzheimer C, Werner S. A novel role of activin in inflammation and repair. J Endocrinol 161:187-193, 1999.
25. Ying SY, Zhang Z, Furst B, Batres Y, Huang G, Li G. Activins and activin receptors in cell growth. Proc Soc Exp Biol Med 214:114-122, 1997.
26. Nishihara T, Okahashi N, Ueda N. Activin A induces apoptotic cell death, Biochem Biophys Res Commun 197:985-991, 1993.
27. Hully JR, Chang L, Schwall RH, Widmer HR, Terrell TG, Gillett NA. Induction of apoptosis in the murine liver with recombinant human activin A. Hepatology 20:854-862, 1994.
28. Wang QF, Tilly KI, Tilly JL, Preffer F, Schneyer AL, Crowley WF Jr, Sluss PM. Activin inhibits basal and androgen-stimulated proliferation and induces apoptosis in the human prostatic cancer cell line, LNCaP. Endocrinology 137:5476-5483, 1996.
29. Chen W, Woodruff TK, Mayo KE, Activin A-induced HepG2 liver cell apoptosis: involvement of activin receptors and smad proteins. Endocrinology 141:1263-1272, 2000.
30. Zhang Z, Zheng J, Zhao Y, Li G, Batres Y, Luo MP, Wan M, Ying SY. Overexpression of activin A inhibits growth, induces apoptosis, and suppresses tumorigenecity in an androgen-sensitive human prostate cancer cell line LNCaP. Int J Oncol 11:727-736, 1997.
31. Danila DC, Inder WJ, Zhang X. Alexander JM, Swearingen B, Hedley-Whyte ET, Klibanski A. Activin effects on neoplastic proliferation of human pituitary tumors. J Clin Endocrinol Metab 85:1009-1015, 2000.
32. Zheng W, Luo MP, Welt C, Lambert-Messerlian G, Sung CJ, Zhang Z, Ying SY, Schneyer AL, Lauchlan SC, Felix JC. Imbalanced expression of inhibin and activin subunits in primary epithelial ovarian cancer. Gynecol Oncol 69:23-31, 1998.
33. Matzuk MM, Finegold MJ, Su J-GJ, Hsueh AJW, Bradley A. α-Inhibin is a tumour-suppressor gene with gonadal specificity in mice. Nature 360:313-319, 1992.
34. Massague J, Cheifetz S, Laiho M, Ralph DA, Weis FMB, Zentella A. Transforming growth factor-β. Cancer Surveys 12:81-103, 1992.
35. Oda S, Nishimatsu S, Murakami K, Ueno N. Molecular cloning and functional analysis of a new activin β subunit: a dorsal mesoderm-inducing activity in Xenopus. Biochem Biophys Res Commun 210:581-588, 1995.
36. Fang J, Yin W, Smiley E, Wang SQ, Bonadio J. Molecular cloning of the mouse activin β E subunit gene. Biochem Biophys Res Commun 228:669-674, 1996.
37. Lau AL, Nishimori K, Matzuk M.M. Structural analysis of the mouse activin β C gene, Biochim Biophys Acta 1307:145-148, 1996.
38. Hotten G, Neidhardt H, Schneider C, Pohl J. Cloning of a new member of the TGF-β family: a putative new activin β C chain. Biochem Biophys Res Commun 206:608-613, 1995.
39. Mellor SL, Cranfield M, Ries R, Pedersen J, Cancilla B, de Kretser D, Groome NP, Mason AJ, Risbridger GP. Localization of activin β(A)-, β(B)-, and β(C)-subunits in humanprostate and evidence for formation of new activin heterodimers of β(C)-subunit. J Clin Endocrinol Metab 85:4851-4858, 2000.
40. Shimonaka M, Inouye S, Shimasaki S, Ling N. Follistatin binds to both activin and inhibin through the common subunit. Endocrinology 128:3313-3315, 1991.
41. de Winter JP, ten Dijke P, de Vries CJ, van Achterberg TA, Sugino H, de Waele P, Huylebroeck D, Verschueren K, van den Eijnden-van Raaij AJ. Follistatins neutralize activin bioactivity by inhibition of activin binding to its type II receptors. Mol Cell Endocrinol 116:105-114, 1996.
42. Iemura S, Yamamoto TS, Takagi C, Uchiyama H, Natsume T, Shimasaki S, Sugino H, Ueno N. Direct binding of follistatin to a complex of bone-morphogenetic protein and its receptor inhibits ventral and epidermal cell fates in early Xenopus embryo. Proc Natl Acad Sci U S A 95:9337-9342, 1998.
43. Krummen LA, Woodruff TK, De Guzman G, Cox ET, Baly DL, Mann E, Garg S, Wong WL, Cossum P, Mather JP. Identification and characterization of binding proteins for inhibin and activin in human serum and follicular fluids. Endocrinology 132:431-443, 1993.
44. Roberts AB, Sporn MB. The transforming growth factor-β. In: Sporn MB, Roberts AB, Eds. Peptide Growth Factors and Their Receptors. Heidelberg: Springer-Verlag, pp419-472, 1990.
45. Niemuller CA, Randall KJ, Webb DJ, Gonias SL, LaMarre J. α 2-macroglobulin conformation determines binding affinity for activin A and plasma clearance of activin A/α 2-macroglobulin complex. Endocrinology 136:5343-5349, 1995.
46. McFarlane JR, Foulds LM, O'Connor AE, Phillips DJ, Jenkin G, Hearn MT, de Kretser DM. Uterine milk protein, a novel activin-binding protein, is present in ovine allantoic fluid. Endocrinology 140:4745-4752, 1999.
47. Massagué J. TGFβ signal transduction. Annu Rev Biochem 67:753-791, 1998.
48. Shimizu A, Kato M, Nakao A, Imamura T, ten Dijke P, Heldin CH, Kawabata M, Shimada S, Miyazono K. Identification of receptors and Smad proteins involved in activin signalling in a human epidermal keratinocyte cell line. Gene Cell 3:125-134, 1998.
49. Hilden K, Tuuri T, Eramaa M, Ritvos O. Expression of type II activin receptor genes during differentiation of human K562 cells and cDNA cloning of the human type IIB activin receptor. Blood 83:2163-2170, 1994.
50. Shuto T, Sarkar G, Bronk JT, Matsui N, Bolander ME. Osteoblasts express types I and II activin receptors during early intramembranous and endochondral bone formation. J Bone Mineral Res 12:403-411, 1997.
51. de Jong FH, de Winter JP, Wesseling JG, Timmerman MA, van Genesen S, van den Eijnden-van Raaij AJ, van Zoelen EJ. Inhibin subunits, follistatin and activin receptors in the human teratocarcinoma cell line Tera-2. Biochem Biophys Res Commun 192:1334-1339, 1993.
52. Thomas TZ, Wang H, Niclasen P, O'Bryan MK, Evans LW, Groome NP, Pedersen J, Risbridger GP. Expression and localization of activin subunits and follistatins in tissues from men with high-grade prostate cancer. J Clin Endocrinol Metabol 82:3851-3858, 1997.
53. Peng C, Ohno T, Koh LY, Chen VT, Leung PC. Human ovary and placenta express messenger RNA for multiple activin receptors. Life Sci 64:983-994, 1999.
54. Demura R, Tajima S, Suzuki T, Yajima R, Odagiri E, Demura H, Kato H, Uchiyama T, Kubo O, Takakura K. Inhibin α, βA subunit and activin type II receptor mRNAs are expressed in human brain tumors. Endocr J 42:307-313, 1995.
55. Shinozaki H, Minegishi T, Nakamura K, Tano M, Miyamoto K, Ibuki Y. Type II and type IIB activin receptors in human placenta. Life Sci 56:1699-1706, 1995.
56. Peng C, Huang TH, Jeung EB, Donaldson CJ, Vale WW, Leung PC. Expression of the type II activin receptor gene in the human placenta. Endocrinology 133:3046-3049, 1993.
57. Kleeff J, Ishiwata T, Friess H, Buchler MW, Korc M. Concomitant over-expression of activin/inhibin β subunits and their receptors in human pancreatic cancer. Int J Cancer 77:860-868, 1998.
58. Yamashita H, ten Dijke P, Huylebroeck D, Sampath TK, Andries M, Smith JC, Heldin C-H, Miyazono K. Osteogenic protein-1 binds to activin type II receptors and induces certain activin-like effects. J Cell Biol 130:217-226, 1995.
59. Liu F, Ventura F, Doody J, Massagué J. Human type II receptor for bone morphogenetic proteins (BMPs): extension of the two-kinase receptor model to the BMPS. Mol Cell Biol 15:3479-3486, 1995.
60. Attisano L, Cárcamo J, Ventura F, Weis FMB, Massagué J, Wrana JL. Identification of human activin and TGF-β type I receptors that form heteromeric kinase complexes with type II receptors. Cell 75:671-680, 1993.
61. Macias-Silva M, Hoodless PA, Tang SJ, Buchwald M, Wrana JL. Specific activation of Smadl signaling pathways by the BMP7 type I receptor, ALK2. J Biol Chem 273:25628-25636, 1998.
62. Chen YG, Massagué J. Smadl recogntion and activation by the ALKI group of TGFβ family receptors. J Biol Chem 274:3672-3677, 1999.
63. Armes NA, Smith JC. The ALK-2 and Alk-4 activin receptors transduce distinct mesoderm-inducing signals during early Xenopus development but do not cooperate to establish thresholds. Development 124:3797-3804. 1997.
64. Hashimoto O, Yamato K, Koseki T, Ohguchi M, Ishisaki A, Shoji H, Nakamura T, Hayashi Y, Sugino H, Hishikara T. The role of activin type I receptors in activin A-induced growth arrest and apoptosis in mouse B-cell hybridoma cells. Cell Signal 10:743-749, 1998.
65. Attisano L, Wrana JL, Montalvo E, Massagué J. Activation of signaling by the activin receptor complex. Mol Cell Biol 16:1066-1073, 1996.
66. Wrana JL, Attisano L, Wieser R, Ventura F, Massagué J. Mechanism of activation of the TGF-β receptor. Nature 370:341-347. 1994.
67. Willis SA, Zimmerman CM, Li LI, Mathews LS. Formation and activation by phosphorylation of activin receptor complexes. Mol Endocrinol 10:367-379, 1996.
68. Huse M, Chen YG, Massague J, Kuriyan J. Crystal structure of the cytoplasmic domain of the type I TGFβ receptor in complex with FKBP12. Cell 96:425-436, 1999.
69. Wu G, Chen YG, Ozdamar B, Gyuricza CA, Chong PA, Wrana JL, Massague J, Shi Y. Structural basis of Smad2 recognition by the Smad anchor for receptor activation. Science 287:92-97, 2000.
70. Lagna G, Hata A, Hemmati-Brivanlou A, Massagué J. Partnership between DPC4 and SMAD proteins in TGFβ signalling pathways. Nature 383:832-836, 1996.
71. Derynck R, Zhang Y, Feng X.H. Smads: transcriptional activators of TGF-β responses. Cell 95:737-740, 1998.
72. Massague J. D. Wotton D. Transcriptional control by the TGF-β/Smad signaling system. EMBO J 19:1745-1754, 2000.
73. Chen X, Rubock MJ, Whitman M. A transcriptional partner of MAD proteins in TGF-β signalling. Nature 383:691-696, 1996.
74. Heldin C-H, Miyazono K,ten Dijke P. TGF-β signalling from cell membrane to nucleus through SMAD proteins. Nature 390:465-471, 1997.
75. Chen X, Weisberg E, Fridmacher V, Watanabe M, Naco G, Whitman M. Smad 4 and FAST-1 in the assembly of activin-responsive factor. Nature 389:85-89, 1997.
76. Xu L, Chen YG, Massague J. The nuclear import function of Smad 2 is masked by SARA and unmasked by TGFβ-dependent phosphorylation. Nat Cell Biol 2:559-562, 2000.
77. Jonk LJ, Itoh S, Heldin CH, ten Dijke P, Kruijer W. Identification and functional characterization of Smad binding element (SBE) in the Jun B promoter that acts as a transforming growth factor-β, activin, and bone morphogenetic protein-inducible enhancer. J Biol Chem 273:21145-21152, 1998.
78. Zhu H, Kavsak P, Abdollah S, Wrana JL, Thomsen GH. A SMAD ubiquitin ligase targets the BMP pathway and affects embryonic pattern formation. Nature 400:687-693, 1999.
79. Kavsak P, Rasmussen RK, Causing CG, Bonni S, Zhu H, Thomsen GH, Wrana JL. Smad7 binds to Smurf 2 to form an E3 ubiquitin ligase that targets the TGF-β receptor for degradation. Mol Cell 6:1365-1375, 2000.
80. Lin X, Liang M, Feng XH. Smurf2 is a ubiquitin E3 ligase mediating proteasome-dependent degradation of Smad 2 in transforming growth factor-β signaling. J Biol Chem 275:36818-36822, 2000.
81. Zhang Y, Chang C, Gehling DJ, Hemmati-Brivanlou A, Derynck R. Regulation of Smad degradation and activity by Smurf 2, an E3 ubiquitin ligase. Proc Natl Acad Sci U S A 98:974-979, 2001.
82. Kretzschmar M, Doody J, Timokhina I, Massague J. A mechanism of repression of TGFβ/Smad signaling by oncogenic Ras. Genes Dev 13:804-816, 1999.
83. 2+-calmodulin-dependent protein kinase II. Mol Cell Biol 20:8103-8111, 2000.
84. Lebrun JJ, Takabe K, Chen Y, Vale W. Roles of pathway-specific and inhibitory Smads in activin receptor signaling. Mol Endocrinol 13:15-23, 1999.
85. Massague J, Chen YG. Controlling TGF-β signaling. Genes Dev 14:627-644, 2000.
86. Feng XH, Derynck R. A kinase subdomain of transforming growth factor-β (TGF-β) type 1 receptor determines the TGF-β intracellular signaling activity. EMBO J 16:3912-3922, 1997.
87. Lo RS, Chen YG, Shi YG, Pavletich N, Massagué J. The L3 loop: a structural motif determining specific interactions between SMAD proteins and TGF-β receptors. EMBO J 17:996-1005, 1998.
88. Chen YG, Hata A, Lo RS, Wotton D, Shi Y, Pavletich N, Massagué J. Determinants of specificity in TGF-β signal transduction. Genes Dev 12:2144-2152, 1998.
89. Armes NA, Neal KA, Smith JC. A short loop on the ALK-2 and ALK-4 activin receptors regulates signaling specificity but cannot account for all their effects on early Xenopus development. J Biol Chem 274:7929-7935, 1999.
90. Chen Y, Bhushan A, Vale W. Smad8 mediates the signaling of the receptor serine kinase. Proc Natl Acad Sci U S A 94:12938-12943, 1997.
91. Hemmati-Brivanlou A, Kelly OG, Melton DA. Follistatin, an antagonist of activin, is expressed in the Spemann organizer and displays direct neuralizing activity. Cell 77:283-295, 1994.
92. DePaolo LV, Mercado M, Guo Y, Ling N. Increased follistatin (activin-binding protein) gene expression in rat anterior pituitary tissue after ovariectomy may be mediated by pituitary activin. Endocrinology 132:2221-2228, 1993.
93. Dalkin AC, Haisenleder DJ, Yasin M, Gilrain JT, Marshall JC. Pituitary activin receptor subtypes and follistatin gene expression in female rats: differential regulation by activin and follistatin. Endocrinology 137:548-554, 1996.
94. Dalkin AC, Haisenleder DJ, Gilrain JT, Aylor K, Yasin M, Marshall JC. Regulation of pituitary follistatin and inhibin/activin subunit messenger ribonucleic acids (mRNAs) in male and female rats: evidence for inhibin regulation of follistatin mRNA in females. Endocrinology 139:2818-2823, 1998.
95. Bilezikjian LM, Corrigan AZ, Blount AL, Vale WW. Pituitary follistafin and inhibin subunit messenger ribonucleic acid levels are differentially regulated by local and hormonal factors. Endocrinology 137:4277-4284, 1996.
96. Yu J, Shao LE, Lemas V, Yu AL, Vaughan J, Rivier J, Vale W. Importance of FSH-releasing protein and inhibin in erythrodifferentiation. Nature 300:765-767, 1987.
97. Lebmn JJ, Vale WW. Activin and inhibin have antagonistic effects on ligand-dependent heteromerization of the type I and type II activin receptors and human erythroid differentiation. Mol Cell Biol 17:1682-1691, 1997.
98. Chen P, Yu YM, Reddi AH. Chondrogenesis in chick limb bud mesodermal cells: reciprocal modulation by activin and inhibin. Exp Cell Res 206:119-127, 1993.
99. Woodruff TK. Hope, hypothesis, and the inhibin receptor: does specific inhibin binding suggest there is a specific inhibin receptor? Endocrinology 140:3-5, 1999.
100. Draper LB, Matzuk MM, Roberts VJ. Cox E, Weiss J, Mather JP, Woodruff TK. Identification of an inhibin receptor in gonadal tumors from inhibin α-subunit knockout mice. J Biol Chem 273:398-403, 1998.
101. Xu J, McKeehan K, Matsuzaki K, McKeehan WL. Inhibin antagonizes inhibition of liver cell growth by activin by a dominant-negative mechanism. J Biol Chem 270:6308-6313, 1995.
102. Martens JW, de Winter JP, Timmerman MA, McLuskey A, van Schaik RH, Themmen AP, de Jong FH. Inhibin interferes with activin signaling at the level of the activin receptor complex in Chinese hamster ovary cells. Endocrinology 138:2928-2936, 1997.
103. Lewis KA, Gray PC, Blount AL, MacConell LA, Wiater E, Bilezikjian LM, Vale W. β-Glycan binds inhibin and can mediate functional antagonism of activin signalling. Nature 404:411-414, 2000.
104. López-Casillas F, Wrana JL, Massagué J. β-Glycan presents ligand to the TGF-β signaling receptor. Cell 73:1435-1444, 1993.
105. Thisse C, Thisse B. Antivin, a novel and divergent member of the TGFβ superfamily, negatively regulates mesoderm induction. Development 126:229-240, 1999.
106. Schreiber SL. Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science 251:283-287, 1991.
107. Wang T, Li B-Y, Danielson PD, Shah PC, Rockwell S, Lechleider RJ, Martin J, Mangnaro T, Donahoe PK. The immunophilin FKBP12 functions as a common inhibitor of the TGFβ family type 1 receptors. Cell 86:435-444. 1996.
108. Chen YG, Liu F, Massagué J. Mechanism of TGFβ receptor inhibition by FKBP12. EMBO J 16:3866-3876, 1997.
109. Okadome T, Oeda E, Saitoh M, Ichijo H, Moses HL, Miyazono K, Kawabata M. Characterization of the interaction of FKBP12 with the transforming growth factor-β type 1 receptor in vivo. J Biol Chem 271:21687-21690, 1996.
110. Onichtchouk D, Chen YG, Dosch R, Gawantka V, Delius H, Massagué J, Niehrs C. Silencing of TGFβ signalling by the pseudoreceptor BAMBI. Nature 401:480-485, 1999.
111. Grotewold L, Plum M, Dildrop R, Peters T, Ruther U. Bambi is coexpressed with Bmp-4 during mouse embryogenesis. Mech Dev 100:327-330, 2001.
112. Ebisawa T, Fukuchi M, Murakami G, Chiba T, Tanaka K, Imamura T, Miyazono K. Smurfl interacts with transforming growth factor-β type I receptor through Smad 7 and induces receptor degradation. J Biol Chem 276:12477-12480, 2001.
113. Tsukazaki T, Chiang TA, Davison AF, Attisano L, Wrana JL. SARA, a FYVE domain protein that recruits Smad 2 to the TGFβ receptor. Cell 95:779-791, 1998.
114. Ishisaki A, Yamato K, Hashimoto S. Nakao A, Tamaki K, Nonaka K, ten Dijke P, Sugino H, Nishihara T. Differential inhibition of Smad6 and Smad 7 on bone morphogenetic protein- and activin-mediated growth arrest and apoptosis in B cells. J Biol Chem 274:13637-13642, 1999.
115. Nakao A, Afrakhte M, Moren A, Nakayama T, Christian JL, Heuchel R, Itoh S, Kawabata M, Heldin NE. Identification of Smad 7, a TGFβ-inducible antagonist of TGF-β signaling. Nature 389:631-635, 1997.
116. Hayashi H, Abdollah S, Qiu Y, Cai J, Xu YY, Gtinnell BW, Richardson MA, Topper JN, Gimbeone MA Jr. The MAD-related protein Smad 7 associates with the TGFβ receptor and functions as an antagonist of TGFβ signaling. Cell 89:1165-1173, 1997.
117. Ishisaki A, Yamato K, Nakao A, Nonaka K, Ohguchi M, ten Dijke P, Nishihara T. Smad 7 is an activin-inducible inhibitor of activin-induced growth arrest and apoptosis in mouse B cells. J Biol Chem 273:24293-24296, 1998.
118. Kitamura K, Aota S, Sakamoto R, Yoshikawa SI, Okazaki K. Smad 7 selectively interferes with different pathways of activin signaling and inhibits erythroid leukemia cell differentiation. Blood 95:3371-3379, 2000.
119. Zimmerman CM, Kariapper MS, Mathews LS. Smad proteins physically interact with calmodulin. J Biol Chem 273:677-680, 1998.
120. Scherer A, Graff JM. Calmodulin differentially modulates Smad1 and Smad 2 signaling. J Biol Chem 275:41430-41438, 2000.
121. Yakymovych I, Ten Dijke P, Heldin CH, Souchelnytskyi S. Regulation of Smad signaling by protein kinase C. FASEB J 15:553-555, 2001.
122. de Caestecker MP, Parks WT, Frank CJ. Castagnino P, Bottaro DP, Roberts AB, Lechleider RJ. Smad 2 transduces common signals from receptor serine-threonine and tyrosine kinases. Genes Dev 12:1587-1592, 1998.
123. Ulloa L, Doody J, Massague J. Inhibition of transforming growth factor-β/SMAD signalling by the interferon-γ/STAT pathway. Nature 397:710-713, 1999.
124. Bitzer M, von Gersdorff G. Liang D, Dominguez-Rosales A, Beg AA,. Rojkind M,. Bottinger EP. A mechanism of suppression of TGF-β/SMAD signaling by NF-κB/RelA. Genes Dev 14:187-197, 2000.
125. Yanagisawa J, Yanigi Y, Masuhiro Y, Suzawa M, Watanebe M, Rashiwagi K, Toriyabe T, Kawabata M, Mrijazeno K, Kato S. Convergence of transforming growth factor-β and vitamin D signaling pathways on SMAD transcriptional coactivators. Science 283:1317-1321, 1999.
126. Subramaniam N, Leong GM, Cock TA, Flanagan JL, Fong C, Eisman JA, Kouzmenko AP. Cross-talk between 1,25-dihydroxyvitamin D3 and transforming growth factor-β signaling requires binding of VDR and Smad 3 proteins to their cognate DNA recognition elements. J Biol Chem 276:15741-15746, 2001.
127. Lo RS, Massagué J. Ubiquitin-dependent degradation of TGF-β-activated Smad2. Nat Cell Biol 1:472-478. 1999.
128. Sugiyama M, Ichida T, Sato T, Ishikawa T, Matsuda Y, Asakura H. Expression of activin A is increased in cirrhotic and fibrotic rat livers. Gastroenterology 114:550-558, 1998.
129. Matsuse T, Ikegami A, Ohge E, Hosoi T, Oka T, Kida K, Fukayama M, Inoue S, Nagase T, Oucki Y, Fukuchi Y. Expression of immunoreactive activin A protein in remodeling lesions associated with interstitial pulmonary fibrosis. Am J Pathol 148:707-713, 1996.
130. Alexander JM, Bikkal HA, Zervas NT, Laws ER Jr, Klibanski A. Tumor-specific expression and alternate splicing of messenger ribonucleic acid encoding activin/transforming growth factor-β receptors in human pituitary adenomas. J Clin Endocrinol Metab 81:783-790, 1996.
131. Zhou Y, Sun H, Danila DC, Johnson SR, Sigai DP, Zhang X, Klibanski A. Truncated activin type I receptor Alk4 isoforms are dominant negative receptors inhibiting activin signaling. Mol Endocrinol 14:2066-2075, 2000.
132. Zhang Z, Zheng J, Zhao Y, Li G, Batres Y, Luo M, Wan M, Ying S. Overexpression of activin A inhibits growth, induces apoptosis, and suppresses tumorigenicity in an androgen-sensitive human prostate cancer cell line LNCaP. Int J Oncol 11:727-736, 1997.
133. Ying SY, Zhang Z. Expression and localization of inhibin/activin subunits and activin receptors in MCF-7 cells, a human breast cancer cell line. Breast Cancer Res Treatment 37:151-160, 1996.
134. Nishihara T, Okahashi N, Ueda N. Activin A induces apoptotic cell death. Biochem Biophys Res Commun 197:985-991, 1993.
135. McCarthy SA, Bicknell R. Inhibition of vascular endothelial cell growth by activin-A. J Biol Chem 268:23066-23071, 1993.
136. Kojima I, Mogami H, Kawamura N, Yasuda H, Shibata H. Modulation of growth of vascular smooth muscle cells by activin A. Exp Cell Res 206:152-156, 1993.
137. Mizuguchi T, Kosaka M, Saito S. Activin A suppresses proliferation of interleukin-3-responsive granulocyte-macrophage colony-forming progenitors and stimulates proliferation and differentiation of interleukin-3-responsive erythroid burst-forming progenitors in the peripheral blood. Blood 81:2891-2897, 1993.
138. Hashimoto O, Yamato K, Koseki T, Ohguchi M, Ishisaki A, Shoji H, Nakamura T, Hayashi Y, Sugino H, Nishihara T. The role of activin type I receptors in activin A-induced growth arrest and apoptosis in mouse B-cell hybridoma cells. Cell Signal 10:743-749, 1998.
139. Sternberg D, Honigwachs-Sha'anani J, Brosh N, Malik Z, Burstein Y, Zipori D. Restrictin-P/stromal activin A kills its target cells via an apoptotic mechanism. Growth Factors 12:277-287, 1995.
140. Kojima I, Mogami H, Kawamura N, Shibata H. Activin A inhibits cell-cycle progression induced by insulin-like growth factor-I in BALB/c 3T3 cells. J Endocrinol 137:99-105, 1993.
141. Schwall RH, Robbins K, Jardieu P, Chang L, Lai C, Terrell TG. Activin induces cell death in hepatocytes in vivo and in vitro. Hepatology 18:347-356, 1993.
142. Zhang YQ, Mashima H. Kanzaki M. Shibata H, Kojima I. Assessment of the role of activin A and transforming growth factor β in the regulation of AML12 cell growth. Hepatology 25:1370-1375, 1997.
143. Hully JR, Chang L, Schwall RH, Widmer HR, Terrell TG, Gillett NA. Induction of apoptosis in the murine liver with recombinant human activin A. Hepatology 20:854-862, 1994.
144. Yamato K, Koseki T, Ohguchi M, Kizaki M, Ikeda Y, Nishihara T. Activin A induction of cell-cycle arrest involves modulation of cyclin D2 and p2lClP1/WAF1 in plasmacytic cells. Mol Endocrinol 11:1044-1052, 1997.
145. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 81:323-330, 1995.
146. Shao L. Frigon NL Jr, Young AL, Yu AL, Mathews LS, Vaughan J, Vale W, Yu J. Effect of activin A on globin gene expression in purified human erythroid progenitors. Blood 79:773-781, 1992.
147. Fukuchi Y, Kizaki M, Yamato K, Kawamura C, Umezawa A, Hata J, Nishihara T, Ikeda Y. Mc1-1, an early-induction molecule, modulates activin A-induced apoptosis and differentiation of CML cells. Oncogene 20:704-713, 2001.
148. Zauberman A, Oren M, Zipori D. Involvement of p21 (Waf1/Cip1), CDK4 and Rb in activin A-mediated signaling leading to hepatoma cell growth inhibition. Oncogene 15:1705-1711, 1997.
149. Zhang Z, Zhao Y, Batres Y, Lin MF, Ying SY. Regulation of growth and prostatic marker expression by activin A in an androgen-sensitive prostate cancer cell line LNCAP. Biochem Biophys Res Commun 234:362-365, 1997.
150. Dalkin AC. Gilrain JT, Bradshaw D, Myers CE. Activin inhibition of prostate cancer cell growth: selective actions on androgen-responsive LNCaP cells. Endocrinology 137:5230-5235, 1996.
151. Ying SY, Zhang Z, Batres Y, Zhao Y, Lin SL, Li G. p53 is involved in the inhibition of cell proliferation mediated by activin A in cultured human prostate cancer LNCaP cells. Int J Oncol 11:591-595, 1997.
152. Miyashita T. Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80:293-299, 1995.
153. Miyashita T, Harigai M, Hanada M, Reed JC. Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res 54:3131-3135, 1994.
154. Lin S, Ying SY. Differentially expressed genes in activin-induced apoptotic LNCaP cells. Biochem Biophys Res Commun 257:187-192, 1999.
155. Koseki T, Yamato K, Ishisaki A, Hashimoto O, Sugino H, Nishihara T. Correlation between Bcl-X expression and B-cell hybridoma apoptosis induced by activin A. Cell Signal 10:517-521, 1998.
156. Koseki T, Yamato K, Krajewski S, Reed JC, Tsujimoto Y, Nishihara T. Activin A-induced apoptosis is suppressed by BCL-2. FEBS Lett 376:247-250, 1995.
157. Denmeade SR, Lin XS, Isaacs JT. Role of programmed (apoptotic) cell death during the progression andtherapy for prostate cancer. Prostate 28:251-265, 1996.
158. Hall M, Peters G. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv Cancer Res 68:67-108, 1996.
159. Sellers WR, Kaelin WG Jr. Role of the retinoblastoma protein in the pathogenesis of human cancer J Clin Oncol 15:3301-3312, 1997.
160. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368:753-756, 1994.
161. Reed JC. Mechanisms of apoptosis avoidancein cancer. Curr Opinion Oncol 11:68-75, 1999.
162. Tsujimoto Y, Cossman J, Jaffe E, Croce CM. Involvement of the bcl-2 gene in human follicular lymphoma. Science. 228:1440-1443. 1985.
163. Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335:440-442, 1988.
164. Silvestrini R, Veneroni S, Daidone MG, Benini E, Boracchi P, Mezzetti M, Di Fronzo G, Rilke F, Veronesi U. The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 86:499-504. 1994.
165. Colombel M, Symmans F. Gil S, O'Toole KM, Chopin D, Benson M, Olsson CA. Korsmeyer S, Buttyan R. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am J Pathol 143:390-400, 1993.
166. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, Tu SM, Campbell ML. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 52:6940-6944, 1992.
167. Hashimoto Y, Shindo-Okada N, Tani M, Takeuchi K, Toma H, Yokota J. Identification of genes differentially expressed in association with metastatic potential of K-1735 murine melanoma by messenger RNA differential display. Cancer Res 56:5266-5271, 1996.
168. Saiki I. Cell adhesion molecules and cancer metastasis. Jap J Pharmacol 75:215-242, 1997.
169. Edvardsen K, Bock E, Jirus S, Frandsen TL, Holst-Hansen C, Moser C, Spang-Thomsen M, Pedersen N, Walsh FS, Vindelov LL, Brunner N. Effect of NCAM-transfection on growth and invasion of a human cancer cell line. APMIS 105:919-930, 1997.
170. Jiang TX, Yi JR, Ying SY, Chuong CM. Activin enhances chondrogenesis
171. Folkman J. Tumor angiogenesis and its inhibitors. Adv Cancer Res 43:175-203, 1985.
172. Kozian DH, Ziche M, Augustin HG. The activin-binding protein follistatin regulates autocrine endothelial cell activity and induces angiogenesis. Lab Invest 76:267-276, 1997.
173. Ziche M, Morbidelli L, Donnini S. Angiogenesis. Exp Nephrol 4:1-14, 1996.
174. Ying SY, Zhang Z, Xing W. Expression of activin and activin receptors in PC3 human prostatic cancer cells. Int J Oncol 6:601-606, 1995.
175. Ying SY, Zhang Z, Huang G. Expression and localization of inhibin/ activin subunits and activin receptors in the normal rat prostate. Life Sci 60:397-401, 1997.
176. Ying SY, Lin S. High performance subtractive hybridization of cD-NAs by covalent bonding between specific complementary nucleotides. BioTechniques 26:966-979, 1999.
177. Ying SY, Lui HM, Lin S. Chuong CM. Generation of full-length cDNA library from single human prostate cancer cells. BioTechniques 27:410-414, 1999.
178. Lin SL, Chuong CM, Widelitz RB, Ying SY. In vivo analysis of cancerous gene expression by RNA-polymerase chain reaction. Nucleic Acids Res 27:4585-4589, 1999.
179. Ying SY, Chuong CM, Lin S. Suppression of activin-induced apoptosis by novel antisense strategy in human prostate cancer cells. Biochem Biophy Res Commun 265:669-673, 1999.
180. Lin SL, Chuong CM, Ying SY. A novel mRNA-cDNA interference phenomenon for silencing bcl-2 expression in human LNCaP cells. Biochem Biophys Res Commun 281:639-644, 2001.